国泰君安证券股份有限公司 关于 中科院成都信息技术股份有限公司发行股份 及支付现金购买资产并募集配套资金 暨关联交易 之部分限售股份解除限售的核查意见 一、公司本次解除限售股份情况 （一）本次解除限售股份的发行及上市情况 2021 年 9 月 27 日，中科院成都信息技术股份有限公司收到中国证券监督 管理委员会（以下简称"中国证监会"）于 2021 年 9 月 23 日出具的《关于同意中 科院成都信息技术股份有限公司向成都中科唯实仪器有限责任公司等发行股份 购买资产并募集配套资金注册的批复》（证监许可[2021]3105 号）。 2021 年 9 月中科信息向成都中科唯实仪器有限责任公司（以下简称"中科唯 实"）、上海仝励实业有限公司（以下简称"上海仝励"）、中国科学院沈阳科学仪器 股份有限公司（以下简称"中科仪"）及陈陵等 32 名特定对象发行股份 8,903,321 股（以下简称"本次发行"或"本次交易"）及支付现金购买其持有的瑞拓科技 100% 股权。 2021 年 11 月 4 日，天职会计师出具了《验资报告》（天职业字[2021]43194 号）。根据该《验资报告》，经审验，截至 2021 年 10 ...

证券代码：300678 证券简称：中科信息 公告编号：2024-050 中科院成都信息技术股份有限公司 关于发行股份及支付现金购买资产并募集配套资金暨 关联交易之部分限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次解除限售的股份为公司发行股份及支付现金购买资产并募集配 套资金暨关联交易事项（即：收购瑞拓科技事项）之发行股份及支付现金 购买资产部分用于支付交易对价的限售股份，其类型属于首发后限售。 2.本次解除限售股份的数量为1,539,612股，占公司总股本的0.5195%。 其中，实际可上市流通的股份数量为1,539,612股，占公司总股本的0.5195%。 3.本次解除限售股份的上市流通日为2024年5月9日（星期四）。 4.本次申请解除股份限售的股东共计13名，共对应13个证券账户。 一、公司股票发行和股本变动情况 （一）本次解除限售股份的发行情况 截至本公告披露日，公司总股本为 296,386,293 股，其中有限售条件 流通股为 12,376,973 股，占公司总股本的 4.18%，无限售条件的流通股 ...

Financial Performance - The company's revenue for Q1 2024 was ¥87,187,750.46, representing a 16.97% increase compared to ¥74,535,937.15 in the same period last year[3] - Net profit attributable to shareholders decreased by 19.02% to ¥7,588,015.41 from ¥9,369,849.59 year-on-year[3] - Basic and diluted earnings per share fell by 45.99% to ¥0.0256 from ¥0.0474 in the same period last year[3] - Net profit for Q1 2024 was ¥6,822,509.44, a decrease of 16.5% from ¥8,166,481.07 in Q1 2023[20] - Total operating revenue for Q1 2024 reached ¥87,187,750.46, an increase of 16.5% compared to ¥74,535,937.15 in the same period last year[19] - Total operating costs amounted to ¥83,914,915.43, up from ¥72,377,873.78, reflecting a year-over-year increase of 16.0%[19] - The total comprehensive income for Q1 2024 was ¥6,822,509.44, down from ¥8,166,481.07 in the same period last year[21] Cash Flow and Assets - The net cash flow from operating activities improved by 22.79%, reaching -¥95,482,299.18 compared to -¥123,663,827.04 in the previous year[3] - Cash received from other operating activities increased by 137.80% to ¥6,718,382.41 compared to ¥2,825,200.43 in the same period last year[7] - The company's cash and cash equivalents decreased to RMB 355,578,148.71 from RMB 501,298,208.11, reflecting a decline of approximately 29%[15] - The total cash and cash equivalents at the end of the period amounted to CNY 346,259,422.11, up from CNY 286,252,306.42 year-over-year[24] - The company reported a total cash outflow of CNY 201,761,642.08 from operating activities, compared to CNY 223,256,415.05 in the previous year[24] Investments and Expenses - Research and development expenses increased by 46.96% to ¥8,435,218.78 from ¥5,739,796.03 year-on-year, indicating a significant investment in innovation[7] - Investment cash payments surged by 532.91% to ¥50,000,000.00 from ¥7,900,000.00, reflecting increased investment in financial assets[7] - Total cash outflow from investment activities was CNY 50,060,729.36, compared to CNY 8,041,955.28 in the same period last year[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 64,436, with the largest shareholder being the Chinese Academy of Sciences Holding Co., Ltd., holding 30.53% of shares[9] - Total equity attributable to shareholders reached ¥871,692,236.23, up from ¥864,104,220.82, reflecting a growth of 0.7%[20] Liabilities and Financial Position - Total liabilities as of Q1 2024 were ¥257,451,468.15, a decrease from ¥398,471,223.60 in the previous year[20] - Current liabilities decreased to RMB 252,816,561.64 from RMB 392,060,318.83, a reduction of about 35%[16] - The company reported a significant reduction in accounts payable, which decreased to RMB 116,259,690.86 from RMB 186,259,289.57, a drop of about 38%[16] Other Notable Points - The company has no new product launches or technological developments mentioned in the report[12] - There are no significant market expansion or acquisition strategies outlined in the current report[12] - The company did not undergo an audit for the first quarter report[25] - The company has not adopted the new accounting standards for the current year[25]

证券代码：300678 证券简称：中科信息 公告编号：2024-048 中科院成都信息技术股份有限公司 第四届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 中科院成都信息技术股份有限公司(以下简称"公司")第四届董 事会第十二次会议于 2024 年 4 月 12 日以电子邮件方式发出会议通知， 于 2024 年 4 月 24 日以联签方式召开。会议应参与表决董事为 9 名，实 际参与表决董事9名。参与表决的董事人数符合法律和公司章程的规定。 会议由公司董事长史志明主持，全体监事、董事会秘书、财务总监列席 了会议。 二、会议审议情况 与会董事对《通知》所列之议案进行了审议并通过了如下事项： （一）审议通过《关于 2024 年第一季度报告的议案》 经与会董事签字并加盖董事会印章的《中科院成都信息技术股份 有限公司第四届董事会第十二次会议决议》 1 / 2 具体内容详见公司于同日在巨潮资讯网(http://www.cninfo.com.cn) 披露的《2024 年第一季度报告》。 表决结果：赞成 9 票；反对 0 票； ...

证券代码：300678 证券简称：中科信息 公告编号：2024-049 中科院成都信息技术股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 中科院成都信息技术股份有限公司(以下简称"公司")第四届监 事会第七次会议于 2024 年 4 月 12 日以电子邮件方式发出会议通知，本 次会议于 2024 年 4 月 24 日以联签方式召开。会议应参与表决监事为 3 名，实际参与表决监事 3 名，参与表决的监事人数符合法律和公司章程 的规定。会议由监事会主席帅红涛主持，董事会秘书列席了会议。 二、监事会会议审议情况 证券代码：300678 证券简称：中科信息 公告编号：2024-049 表决结果：赞成 3 票；反对 0 票；弃权 0 票。 经与会监事审议并投票表决，通过了如下事项： （一）审议通过《关于 2024 年第一季度报告的议案》 经审核，监事会认为董事会在《2024 年第一季度报告》的编制和审 核过程中，工作严谨细致，审核程序符合相关法律、行政法规、中国证 监会和深圳证券交易所的规定，报告的内 ...

证券代码：300678 证券简称：中科信息 公告编号：2024-044 中科院成都信息技术股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会未出现否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 3.本公告所称中小投资者是指除以下股东之外的公司其他股东： （1）单独或者合计持有公司 5%以上股份的股东； （2）持有公司股份的公司董事、监事、高级管理人员。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间： 现场会议：2024 年 4 月 22 日（星期一）下午 14:30； 网络投票：2024 年 4 月 22 日，其中通过深圳证券交易所交易系统 进行网络投票的具体时间为 2024 年 4 月 22 日上午 9:15-9:25 和 9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票系统 进行网络投票的具体时间为 2024 年 4 月 22 日上午 9：15 至下午 15:00 期间的任意时间。 1 / 6 2.现场会议地址：四 ...

北京市天元（成都）律师事务所 关于中科院成都信息技术股份有限公司 2023 年度股东大会的法律意见 （2024）天（蓉）意字第 19 号 致：中科院成都信息技术股份有限公司 中科院成都信息技术股份有限公司（以下简称"公司"）2023 年度股东大会 （以下简称"本次股东大会"）采取现场投票与网络投票相结合的方式，现场会议 于 2024 年 4 月 22 日（星期一）下午 14:30 在四川天府新区兴隆街道科智路 1369 号公司南楼 7 楼 A718 会议室召开。北京市天元（成都）律师事务所（以下简称"本 所"）接受公司聘任，指派本所律师参加本次股东大会现场会议，并根据《中华人 民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、《上 市公司股东大会规则》（以下简称"《股东大会规则》"）以及《中科院成都信息 技术股份有限公司章程》（以下简称"《公司章程》"）等有关规定，就本次股东 大会的召集、召开程序、出席现场会议人员的资格、召集人资格、会议表决程序及 表决结果等事项出具本法律意见。 为出具本法律意见，本所律师审查了《中科院成都信息技术股份有限公司第四 届董事会第十一次会议决议公告》《中科院成都 ...

国泰君安证券股份有限公司关于 中科院成都信息技术股份有限公司 发行股份及支付现金购买资产并募集配套 资金暨关联交易 之 2023 年度持续督导意见 暨持续督导总结报告 独立财务顾问（主承销商） 二零二四年四月 1 特别提示 国泰君安证券股份有限公司接受委托，担任中科院成都信息技术股份有限公 司发行股份及支付现金购买资产暨关联交易之独立财务顾问。根据《公司法》、 《证券法》、《上市公司重大资产重组管理办法》和《深圳证券交易所创业板股票 上市规则》等法律规范的有关规定，按照证券行业公认的业务标准、道德规范， 本着诚实信用、勤勉尽责的态度，本独立财务顾问经过审慎核查，结合上市公司 2023 年年度报告，出具了本《国泰君安证券股份有限公司关于中科院成都信息 技术股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易之 2023 年度持续督导意见》（以下简称"本持续督导意见"）。 本独立财务顾问对上市公司发行股份及支付现金购买资产并募集配套资金 暨关联交易实施情况所出具持续督导意见的依据是上市公司、交易对方、标的公 司等重组相关各方提供的资料，重组相关各方已向本独立财务顾问保证，其所提 供的为出具本持续督导意见 ...

国泰君安证券股份有限公司 关于中科院成都信息技术股份有限公司 发行股份及支付现金购买资产并募集配套资 金暨关联交易之 2023 年度业绩承诺完成情况的核查意见 国泰君安证券股份有限公司（简称"国泰君安证券"、"本独立财务顾问"） 作为中科院成都信息技术股份有限公司（简称"中科信息"、"上市公司"、 "公司"）发行股份及支付现金购买资产并募集配套资金暨关联交易（简称"重 大资产重组"、"本次交易"）的独立财务顾问，根据《证券发行上市保荐业务 管理办法》《上市公司重大资产重组管理办法》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等相关法律法规的规定，对业绩承诺方关于成都瑞拓科技有限责任公司（以 下简称"瑞拓科技"或"标的资产"）业绩承诺实现情况进行了核查，情况如下， 具体核查情况如下： 一、业绩承诺及补偿安排 （一）业绩承诺情况 盈利承诺期内，标的资产截至当期期末累积实现净利润数低于截至当期期末 累积承诺净利润数，盈利补偿主体应当对上市公司进行补偿，且每个盈利补偿主 体仅对其个人的应补偿金额承担补偿责任，不对其他盈利补偿主体应补偿金额承 担补偿 ...

Financial Performance - The company's operating revenue for 2023 was ¥591,402,263.43, representing a 6.61% increase compared to ¥554,711,552.61 in 2022[22]. - Net profit attributable to shareholders for 2023 was ¥38,465,351.47, a decrease of 23.35% from ¥50,265,875.46 in 2022[22]. - The net profit after deducting non-recurring gains and losses was ¥23,206,503.16, down 36.16% from ¥36,434,444.76 in 2022[22]. - The net cash flow from operating activities decreased by 61.58% to ¥51,220,937.48 from ¥133,335,608.46 in 2022[22]. - Basic earnings per share for 2023 were ¥0.1507, a decline of 40.97% compared to ¥0.2553 in 2022[22]. - Total assets at the end of 2023 reached ¥1,263,044,289.24, an increase of 7.13% from ¥1,179,034,494.46 at the end of 2022[22]. - Net assets attributable to shareholders increased by 3.50% to ¥864,104,220.82 from ¥834,950,028.88 in 2022[22]. - The weighted average return on net assets for 2023 was 4.53%, down from 6.27% in 2022[22]. - The overall gross profit margin decreased due to a higher proportion of lower-margin information technology solutions, impacting the company's profitability[126]. - Operating profit was 41.74 million yuan, down 20.82% year-on-year, while total profit decreased by 21.99% to 42.46 million yuan[160]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.5 yuan per 10 shares to all shareholders, based on a total of 296,386,293 shares[5]. - The company has not proposed any bonus shares for the current fiscal year, maintaining a focus on cash dividends[5]. - The proportion of customers with over 5 years of cooperation reached 34.95%, indicating strong customer loyalty[123]. Governance and Reporting - The board of directors has confirmed the accuracy and completeness of the annual report, ensuring no misleading statements or omissions[5]. - The financial report is signed and guaranteed by the company's responsible personnel, ensuring its authenticity[5]. - The report period covers from January 1, 2023, to December 31, 2023[14]. - The company is committed to transparency and has made all relevant documents available for public inspection[11]. - The board meeting to review the report was attended by all directors, indicating strong governance practices[5]. Risk Management - The company emphasizes the importance of understanding the risks associated with forward-looking statements in the report[5]. - The report includes a detailed section on risks faced by the company and corresponding mitigation measures[5]. - The company reported uncertainty regarding its ability to continue as a going concern based on recent financial performance[23]. - The company is focused on maintaining a robust financial position while addressing potential operational risks[5]. AI Industry Insights - The AI industry is experiencing rapid growth, with over 200 AI models released in China by the end of 2023, indicating a strong market demand[36]. - The core AI industry in China has reached a scale of 500 billion yuan, with over 4,400 companies involved[38]. - By 2035, the scale of China's AI industry is expected to reach 17.3 trillion yuan, accounting for 30.6% of the global market[38]. - The Chinese government has implemented a series of supportive policies for AI development, including the "New Generation AI Standard System Construction Guide" and the "Three-Year Action Plan for New Data Centers (2021-2023)"[39]. - The AI sector is expected to benefit from advancements in disruptive technologies and new business models, fostering new production capabilities[38]. Technological Development and Innovation - The company is focusing on the integration of artificial intelligence technologies with various sectors, including finance, agriculture, and healthcare, to enhance digital economic development[42]. - The company is committed to fostering a competitive digital industry cluster with international competitiveness through high-quality digital industrial development measures[43]. - The company is enhancing its AI capabilities by focusing on algorithm evaluation frameworks to address potential risks in AI applications[42]. - The company is actively promoting the development of digital infrastructure to support the integration of AI technologies into traditional industries[43]. - The company is leveraging new technologies such as large models in industry applications, indicating a commitment to innovation[93]. Market Expansion and Strategic Partnerships - The company has established subsidiaries and offices in 13 provinces and regions, expanding its sales channels and coverage[138]. - The company has formed strategic partnerships with organizations like the Chinese Academy of Sciences to enhance collaboration in chip technology, computing power, and AI applications[138]. - The company is exploring strategic partnerships and acquisitions to further enhance its market presence and technological capabilities[148]. - The company has successfully expanded its marketing network, covering 8 provinces in China, improving local service quality[161]. Research and Development - The company has a robust research and development foundation supported by the Chinese Academy of Sciences, ensuring continuous innovation and talent cultivation in key technology areas[121]. - The company’s R&D investment amounted to ¥38,113,856.81 in 2023, representing 6.44% of total revenue, a decrease from 7.93% in 2022[192]. - The number of R&D personnel decreased by 20% from 300 in 2022 to 240 in 2023, with the proportion of R&D staff dropping from 46.22% to 37.38%[191]. - The company has added 36 new authorized patents and registered 74 software copyrights during the reporting period[148]. Sector-Specific Developments - The company has successfully integrated and managed the operations of Ruidao Technology, achieving performance commitments for the period from 2021 to 2023[172]. - The company has developed a comprehensive information solution for the oil and gas sector, partnering with major domestic oil companies like PetroChina and Sinopec[118]. - The company has successfully expanded its market influence beyond Sichuan province, enhancing its competitive edge in the government information services sector[120]. - The company is actively involved in the development of smart medical solutions, including AI-assisted anesthesia systems[170]. Financial Position and Cash Flow - Cash and cash equivalents increased to $501,298,208, representing 39.69% of total assets, up from 36.67% at the beginning of 2023, reflecting a 3.02% increase in proportion[200]. - The net cash flow from operating activities fell by 61.58% to ¥51,220,937.48, attributed to a decrease in new contract amounts and increased external procurement costs[196]. - Investment cash inflow surged by 812.13% to ¥89,961,580.06, while investment cash outflow decreased by 36.96% to ¥44,673,095.41, resulting in a net cash flow increase of 174.25%[196].